Narrative review of cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases in ovarian cancer

Boerner, Thomas; Zivanovic, Oliver; Dennis, S.

doi:10.21037/jgo-20-274

Cited by 4 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most recent meta-analysis [ 116 , 117 , 118 , 119 ] reported improved PFS after CRS and HIPEC in patients with primary advanced OC, even after adjustment for potential confounders (such as age, stage, neoadjuvant chemotherapy, grade, ECOG status [ 120 ], and histology). However, due to the retrospective nature, their results should be interpreted with caution, conditioned by a wide variety of chemotherapeutic regimens [ 121 ].…”

Section: Treatment Of Ovarian Cancer Metastatic Peritoneal Surface Ma...mentioning

confidence: 99%

See 1 more Smart Citation

Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes

Marrelli

Ansaloni²,

Federici

et al. 2022

Cancers

View full text Add to dashboard Cite

Ovarian cancer is the eighth most common neoplasm in women with a high mortality rate mainly due to a marked propensity for peritoneal spread directly at diagnosis, as well as tumor recurrence after radical surgical treatment. Treatments for peritoneal metastases have to be designed from a patient’s perspective and focus on meaningful measures of benefit. Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery with regional chemotherapy, has been proposed to treat advanced ovarian cancer. Preliminary results to date have shown promising results, with improved survival outcomes and tumor regression. As knowledge about the disease process increases, practice guidelines will continue to evolve. In this review, we have reported a broad overview of advanced ovarian cancer management, and an update of the current evidence. The future perspectives of the Italian Society of Surgical Oncology (SICO) are discussed conclusively.

show abstract

Section: Treatment Of Ovarian Cancer Metastatic Peritoneal Surface Ma...mentioning

confidence: 99%

“…Furthermore, Boerner et al recommend special consideration for OC patients at higher risk for toxicity: a preoperative creatinine level of 1.0–1.5 mg/dL, non-insulin dependent diabetes mellitus, baseline neuropathy and baseline hearing loss [ 121 ].…”

Section: Treatment Of Ovarian Cancer Metastatic Peritoneal Surface Ma...mentioning

confidence: 99%

Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes

Marrelli

Ansaloni²,

Federici

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…This has resulted in survival rates for OC that have not changed significantly for decades, even in resource-rich countries such as the United States and Canada, and remain at only 47% 5 years after diagnosis (Lheureux2019). Currently, cytoreductive surgery combined with platinum-based chemotherapy is considered the standard treatment option for OC [ 2 ]. Since therapeutic strategies are constantly being adjusted, the quality of life of many patients has been improved.…”

Section: Introductionmentioning

confidence: 99%

Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing

Liu

Zheng

et al. 2023

J Ovarian Res

View full text Add to dashboard Cite

Exosomal miRNAs are known to play important roles in ovarian cancer and chemotherapeutic resistance. However, a systematic evaluation of characteristics of exosomal miRNAs involved in cisplatin resistance in ovarian cancer remains totally unclear. Exosomes (Exo-A2780, Exo-A2780/DDP) were extracted from cisplatin-sensitive cells (A2780) and cisplatin-resistant cells (A2780/DDP). Differential exosomal miRNA expression profiles were found by high-throughput sequencing (HTS). Target genes of the exo-miRNAs were predicted by using two online databases to increase the prediction accuracy. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were utilized to find biological relationships with chemoresistance. RT‒qPCR of three exosomal miRNAs was performed, and a protein‒protein interaction (PPI) network was established to identify the hub genes. The GDSC database was used to prove the association between hsa-miR-675-3p expression and the IC50 value. An integrated miRNA–mRNA network was constructed to predict miRNA–mRNA associations. The connection between hsa-miR-675-3p and ovarian cancer was discovered by immune microenvironment analyses. The upregulated exosomal miRNAs could regulate gene targets through signalling pathways such as the Ras, PI3K/Akt, Wnt, and ErbB pathways. GO and KEGG analyses indicated that the target genes were involved in protein binding, transcription regulator activity and DNA binding. The RT‒qPCR results were consistent with the HTS data, and the results of PPI network analysis suggested that FMR1 and CD86 were the hub genes. GDSC database analysis and construction of the integrated miRNA–mRNA network suggested that hsa-miR-675-3p was associated with drug resistance. Immune microenvironment analyses showed that hsa-miR-675-3p was crucial in ovarian cancer. The study suggested that exosomal hsa-miR-675-3p is a potential target for treating ovarian cancer and overcoming cisplatin resistance.

show abstract

“…Hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreductive surgery offers a one-time opportunity to provide treatment to the peritoneal cavity, while the patient is anesthetized [6]. Although HIPEC retains the benefits and mitigates the concerns associated with intraperitoneal chemotherapy for ovarian cancer, the efficacy, safety, and treatment paradigm for its use remain controversial [2,6,7 ▪ ,8–11,12 ▪ ,13,14].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?

Praiss

Moukarzel

Zivanovic

2022

Current Opinion in Obstetrics &Amp; Gynecology

Self Cite

View full text Add to dashboard Cite

Purpose of reviewOur objective is to provide a history, rationale, and review of the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of ovarian cancer.Recent findingsIn the last decade, there has been an increase in the literature regarding HIPEC in the treatment of ovarian cancer. The rationale for HIPEC extends from earlier trials demonstrating improved survival using intraperitoneal chemotherapy. HIPEC provides a one-time opportunity for intraperitoneal chemotherapy at the time of cytoreduction and with the addition of hyperthermia. Cisplatin HIPEC has been demonstrated to have a survival benefit when used in the interval cytoreductive setting. In terms of safety, nephroprotection remains a key concern when administering HIPEC. Sodium thiosulfate provides nephroprotection and should be considered when performing HIPEC. Various institutions have created multidisciplinary protocols for administering HIPEC, which include operating room staff, nursing, anesthesia, pharmacy, and surgical teams.SummaryHIPEC has a role in the treatment paradigm of ovarian cancer. Currently, HIPEC is approved in the interval cytoreductive surgery setting. Further trials are needed to understand the appropriate timing, chemotherapeutic agents, and protocolization of HIPEC.

show abstract

Narrative review of cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases in ovarian cancer

Cited by 4 publications

References 30 publications

Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes

Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes

Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing

Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?

Contact Info

Product

Resources

About